Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-20-038885
Date:2020-06-24
Issuer: CUE BIOPHARMA, INC. (CUE)
Original Submission Date:

Reporting Person:

FLETCHER AARON G.L.
C/O CUE BIOPHARMA, INC.
21 ERIE STREET CAMBRIDGE, MA 02139

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2020-06-24 P 4,547 a $24.64 155,499 direct
COMMON STOCK 2020-06-24 P 2,953 a $25.24 158,452 direct
COMMON STOCK 2020-06-24 0 $0.00 8,867 indirect
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 the price reported in column 4 is a weighted average price. these shares were purchased in multiple transactions at prices ranging from $23.92 to $24.90, inclusive. the reporting person undertakes to provide to cue biopharma, inc., any security holder of cue biopharma, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this form 4.
f2 the price reported in column 4 is a weighted average price. these shares were purchased in multiple transactions at prices ranging from $24.91 to $25.74, inclusive. the reporting person undertakes to provide to cue biopharma, inc., any security holder of cue biopharma, inc., or the staff of the securities and exchange commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this form 4.
WhaleWisdom Logo

Elevate your investments